Monica Michele Carrozzo McSherry: Converging Pathways Between Homocysteine and Cholesterol in Cardiovascular Risk
Monica Michele Carrozzo McSherry, Registered Nutritional Therapist at Healthmatters Health Store, Freelance Writer at Dulwich Nutrition, shared a post on LinkedIn:
“Homocysteine (Hcy), a sulfur-containing amino acid derived from methionine metabolism, is remethylated to methionine via folate and vitamin B12 or transsulfurated to cystathionine via vitamin B6.
Elevated plasma Hcy, or hyperhomocysteinemia, is a recognized risk factor for atherosclerosis, primarily through endothelial dysfunction, oxidative stress, and inflammation.
Hcy promotes reactive oxygen species formation, reduces nitric oxide bioavailability, and stimulates pro-inflammatory pathways, accelerating vascular injury.
Cholesterol, particularly LDL-C, drives atherogenesis through subendothelial deposition, oxidation, and foam cell formation, whereas HDL-C facilitates reverse cholesterol transport and vascular protection.
Evidence indicates that hyperhomocysteinemia interacts with lipid metabolism by increasing LDL oxidation, impairing HDL function, and modulating hepatic cholesterol synthesis.
Oxidized LDL generated under elevated Hcy conditions is highly atherogenic, while inhibition of HDL-associated paraoxonase-1 reduces antioxidant defense, compounding vascular risk.
Genetic variants affecting homocysteine metabolism, such as MTHFR C677T, associate with elevated Hcy and altered lipid profiles, highlighting a combined genetic predisposition to cardiovascular disease.
Epidemiological data suggest additive risk when hyperhomocysteinemia coexists with dyslipidemia.
While B-vitamin supplementation lowers Hcy levels, effects on lipid profiles and cardiovascular outcomes are inconsistent, reflecting complex interactions involving oxidative stress, endothelial repair, and lipid oxidation.
In summary, homocysteine and cholesterol are intertwined modulators of cardiovascular risk.
Hyperhomocysteinemia exacerbates LDL oxidation and HDL dysfunction, potentiating atherogenesis.
Beyond lipid-lowering therapies, nutritional strategies targeting Hcy through folate, B12, and B6 may provide complementary cardiovascular protection, particularly in genetically susceptible populations.
Future research should clarify the mechanistic crosstalk and therapeutic implications of the homocysteine-cholesterol axis.”
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers